Birchview Capital LP bought a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 32,110 shares of the company's stock, valued at approximately $494,000. Birchview Capital LP owned 0.22% of Inhibrx as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also made changes to their positions in the company. PNC Financial Services Group Inc. bought a new stake in shares of Inhibrx in the fourth quarter valued at about $28,000. Natixis acquired a new position in shares of Inhibrx in the 4th quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Inhibrx during the 4th quarter worth approximately $47,000. New York State Common Retirement Fund acquired a new stake in Inhibrx in the 4th quarter valued at $53,000. Finally, Corebridge Financial Inc. bought a new stake in Inhibrx in the fourth quarter valued at $89,000. Institutional investors own 82.46% of the company's stock.
Inhibrx Price Performance
Shares of INBX stock traded up $0.08 during trading hours on Thursday, hitting $12.41. 35,333 shares of the company's stock were exchanged, compared to its average volume of 196,342. The stock's 50-day moving average is $12.97 and its 200-day moving average is $14.00. Inhibrx, Inc. has a 52 week low of $10.59 and a 52 week high of $34.75.
Inhibrx (NASDAQ:INBX - Get Free Report) last issued its quarterly earnings results on Monday, March 17th. The company reported ($3.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The firm had revenue of $0.10 million during the quarter. Equities research analysts expect that Inhibrx, Inc. will post 104.88 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Separately, JMP Securities reiterated a "market perform" rating on shares of Inhibrx in a research report on Wednesday, January 22nd.
Read Our Latest Analysis on INBX
Inhibrx Profile
(
Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
See Also
Before you consider Inhibrx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx wasn't on the list.
While Inhibrx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
